Rheumatoid Arthritis
“Our study, to our knowledge, is the first population-based study that investigates the association between working in cold environment and risk of developing RA among healthy individuals,” wrote Pingling Zeng, PhD, Institute of Environmental Medicine, Karolinska University, Stockholm, Sweden, and colleagues.
A post hoc analysis of the recent OPTIMA trial showed that treatment-naïve patients with early rheumatoid arthritis treated with methotrexate monotherapy achieved good clinical outcomes compared with those who initiated therapy with methotrexate plus adalimumab.
Biologic disease-modifying antirheumatic drugs have been the cornerstone of therapy for patients with rheumatoid arthritis (RA) for more than a decade. Although highly effective, these therapies can be expensive and access to them may be limited for some patients.
In an interview with Value-Based Care in Rheumatology, Dr Fraenkel explained the need for an efficient, personalized approach to shared decision-making that addresses patient-specific concerns.
“One of the biggest challenges in the management of RA is monitoring disease effectively, in order to avoid missing flare-ups,” said Dr Walker and colleagues, adding that the use of patient-reported outcomes to complement disease monitoring is recommended by the European League Against Rheumatism.
This is an analysis of the double-blind, placebo-controlled period 1 of the randomized phase 3 study that evaluated upadacitinib in patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
The MONARCH trial showed that subcutaneous sarilumab was superior to adalimumab monotherapy in reducing disease activity and improving physical function in active rheumatoid arthritis. Patients who completed the initial double-blind phase in MONARCH continued to the open-label extension and received sarilumab monotherapy.
Although tocilizumab has been known to elevate serum lipid levels in patients with RA, its cardiovascular effects are unknown.
Sarilumab, a human monoclonal antibody against interleukin-6 receptors, is currently approved for patients with moderate-to-severe rheumatoid arthritis (RA), based on efficacy and safety data from several clinical trials.
The analysis of the COMPACT trial sought to demonstrate noninferiority of tocilizumab alone versus tocilizumab plus methotrexate (MTX) in maintaining clinical response in patients with rheumatoid arthritis (RA) who achieve low disease activity (LDA) following treatment with tocilizumab plus MTX.
